Literature DB >> 10404053

Interleukin-12 regulates the production of Bacille Calmette-Guérin-induced interferon-gamma from human cells in a CD40-dependent manner.

P Méndez-Samperio1, H E Ayala-Verdin, A Trejo-Echeverria.   

Abstract

Interferon (IFN)-gamma is a cytokine which plays a critical role in the host defence against human tuberculosis infection. There is evidence that interleukin (IL)-12 can exert a potent effect in stimulating the production of IFN-gamma, and it is well known that a costimulatory signal provided by CD40 may enhance IL-12 production by monocytes/macrophages. However, it is unclear whether CD40-CD40L stimulation is able to regulate the production of mycobacterial-induced IFN-gamma through an IL-12-dependent pathway. In this study, we investigated the capacity of the Bacille Calmette-Guérin (BCG) strain of Mycobacterium bovis to induce the production of interferon-gamma through IL-12 and/or CD40 costimulation from human cells. Our data demonstrate that anti-IL-12 antibodies markedly reduced the levels of IFN-gamma produced by the BCG-stimulated human cells, while exogenous recombinant (r)IL-12 up-regulated the production of IFN-gamma. In addition, the stimulatory effect of IL-12 on BCG-induced IFN-gamma secretion was specific, as it was significantly abolished in the presence of anti-IL-12 antibodies. We also observed that the presence of an anti-CD40L monoclonal antibody significantly inhibited the production of IL-12 and IFN-gamma by human cells activated with BCG. In contrast, an isotype control antibody showed no effect on cytokine production. Furthermore, the presence of a trimeric soluble CD40L agonist (CD40T) in cultures increased the production of IL-12 and IFN-gamma. Importantly, the stimulatory capacity of CD40T on BCG-induced IFN-gamma secretion was blocked by a monoclonal antibody against IL-12, indicating that the effect of CD40T on T cells was mediated through IL-12. Together, these studies are the first to demonstrate that BCG-induced IFN-gamma production by human cells appears to be mediated by IL-12 in a CD40-dependent manner and suggest that CD40-CD40L activation may be a critical mediator in regulating the immune response to stimulation with BCG.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404053

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

2.  Mycobacterium bovis BCG-induced granuloma formation depends on gamma interferon and CD40 ligand but does not require CD28.

Authors:  L H Hogan; W Markofski; A Bock; B Barger; J D Morrissey; M Sandor
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  Enhanced interleukin-12 and CD40 ligand activities but reduced Staphylococcus aureus Cowan 1-induced responses suggest a generalized and progressively impaired type 1 cytokine pattern for human schistosomiasis.

Authors:  Silvia M L Montenegro; Frederico G C Abath; Ana Lúcia C Domingues; Wlademir G Melo; Clarice N L Morais; Eridan M Coutinho; Siddhartha Mahanty; Thomas A Wynn
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

4.  Exposure of cord blood to Mycobacterium bovis BCG induces an innate response but not a T-cell cytokine response.

Authors:  M L V Watkins; P L Semple; B Abel; W A Hanekom; G Kaplan; S R Ress
Journal:  Clin Vaccine Immunol       Date:  2008-09-24

5.  The phenolic glycolipid of Mycobacterium tuberculosis differentially modulates the early host cytokine response but does not in itself confer hypervirulence.

Authors:  Daniel Sinsimer; Gaelle Huet; Claudia Manca; Liana Tsenova; Mi-Sun Koo; Natalia Kurepina; Bavesh Kana; Barun Mathema; Salvatore A E Marras; Barry N Kreiswirth; Christophe Guilhot; Gilla Kaplan
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

6.  CD40 ligand (CD154) does not contribute to lymphocyte-mediated inhibition of virulent Mycobacterium tuberculosis within human monocytes.

Authors:  Rhonda Larkin; Christopher D Benjamin; Yen-Ming Hsu; Qing Li; Lynn Zukowski; Richard F Silver
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.